clenbuterol
Phase 2Small molecule
clenbuterol is one of 60 small molecule programs targeting Atrophy. It is currently in Phase 2.
4
Indications
9
Total Trials
2
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
48 competitors in Memory
#DrugCompanyPhaseTrials
1Aricept
EisaiApproved
Ritalin
NovartisApproved
Myrbetriq
AstellasApproved
Inderal
WWyeth-Lederle Vaccines
Approved
Ambien
PPurdue Pharma LP
Approved
Intuniv
PPromius Pharma, LLC
Approved
Bendopa
MMerz North America, Inc.
Approved
Pitocin
RRetrophin
Approved
Rilutek
AAzurity Pharmaceuticals
Approved
Mifeprex
DDanco
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pompe Disease2 trials
Safety and Efficacy of Clenbuterol in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy
Completed·—·Phase 1/2·NCT01942590·17 enrolled
Phase II Clinical Trial of Clenbuterol in Adult Patients With Pompe Disease
Withdrawn·—·Phase 2·NCT04094948
Amyotrophic Lateral Sclerosis1 trial
Clenbuterol on Motor Function in Individuals With Amyotrophic Lateral Sclerosis
Completed·—·Phase 2·NCT04245709·25 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for clenbuterol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- UUniversity of Copenhagen